Positive Airway Pressure Devices - Market Insights, Competitive Landscape, and Market Forecast - 2034

Positive Airway Pressure Devices Market Summary

Overview:

• The Positive Airway Pressure Devices market is estimated at USD 4.85 billion in 2025 and is projected to reach USD 8.92 billion by 2034. Growth is anchored in the high and largely undiagnosed burden of obstructive sleep apnea, rising obesity and population ageing, expanding home-based diagnosis and care, and continuous innovation in connected, auto-adjusting therapy devices.
• The global Positive Airway Pressure Devices market is growing at a CAGR of 7.0% during the forecast period from 2026 to 2034.
• By device type, the continuous positive airway pressure (CPAP) devices segment dominated the Positive Airway Pressure Devices market with a 52% share in 2025.
• By age group, the adults segment dominated the Positive Airway Pressure Devices market with a 94% share in 2025.
• By end-user, the homecare settings segment dominated the Positive Airway Pressure Devices market with a 71% share in 2025.
• North America dominated the global Positive Airway Pressure Devices market revenue with a 40% share in 2025, representing the highest regional market share globally.

Positive airway pressure (PAP) devices are medical devices that deliver a controlled stream of pressurized air through a mask and tubing to keep the upper airway open during sleep. They are the first-line therapy for moderate-to-severe obstructive sleep apnea (OSA) and an important treatment for other forms of sleep-disordered breathing and chronic respiratory failure. A typical system combines a flow generator, a heated humidifier, a patient interface (nasal, nasal pillow, or full-face mask), and tubing, and increasingly adds wireless connectivity and cloud-based software that let clinicians and providers monitor usage, leaks, and residual events remotely. The market is organized by device type across continuous positive airway pressure (CPAP) devices, auto-titrating positive airway pressure (APAP) devices, bi-level positive airway pressure (BiPAP) devices, and others; by age group across adults and pediatrics; by end-user across hospitals, clinics, and homecare settings; and by geography. Driven by the high prevalence of OSA, rising obesity and ageing populations, the shift toward home-based sleep testing and therapy, and steady innovation in connected and AI-enabled devices, PAP devices have become the cornerstone of sleep apnea management and an essential part of the home respiratory care ecosystem.

Positive Airway Pressure Devices Market Key Growth Drivers

• The high and rising prevalence of obstructive sleep apnea is the central demand driver, with a widely cited 2019 estimate in The Lancet Respiratory Medicine of nearly 936 million adults aged 30 to 69 living with OSA worldwide, of whom roughly 425 million have moderate-to-severe disease.
• Rising obesity, population ageing, and associated cardiometabolic comorbidities are expanding the at-risk population, with the World Health Organization reporting that more than 1 billion people worldwide are living with obesity.
• Growing diagnosis rates, supported by home sleep apnea testing, wearable screening, and greater physician and consumer awareness, are converting a large undiagnosed pool into new PAP therapy starts.
• The shift of care to the home, supported by established reimbursement for PAP therapy in major markets, is sustaining recurring demand for devices, masks, and accessories through homecare providers.
• Technological innovation in auto-adjusting algorithms, quieter and more compact designs, integrated humidification, wireless connectivity, and remote patient monitoring is improving comfort and adherence and driving device upgrades.
• Replacement demand from ageing device fleets and the market realignment that followed the Philips Respironics recall and its US sales restrictions are redistributing demand toward other manufacturers.
• The convergence of rising disease prevalence, expanding diagnosis, home-based care, and technology-led adherence improvement is expected to sustain steady growth in the market through 2034.

Key Companies in Positive Airway Pressure Devices Market

The competitive landscape is led by the following active device manufacturers and respiratory care providers:

• ResMed
• Koninklijke Philips N.V.
• Fisher & Paykel Healthcare Limited
• APEX MEDICAL CORP
• ARMSTRONG MEDICAL (an EAKIN Company)
• Smiths Medical
• Compumedics Limited
• VYAIRE MEDICAL, INC.
• Somnera Inc
• 3B Medical Inc.

Factors Contributing to the Growth of the Positive Airway Pressure Devices Market

Market Drivers

Rising Prevalence of Obstructive Sleep Apnea

Obstructive sleep apnea is the most important driver of the Positive Airway Pressure Devices market. A widely cited 2019 analysis published in The Lancet Respiratory Medicine estimated that nearly 936 million adults aged 30 to 69 live with OSA globally, including about 425 million with moderate-to-severe disease, and the large majority remain undiagnosed. OSA is associated with hypertension, atrial fibrillation, stroke, type 2 diabetes, daytime sleepiness, and accidents, which raises its clinical and economic importance for health systems and employers. Because PAP therapy is the first-line, guideline-endorsed treatment for moderate-to-severe OSA and has the most established evidence base, every newly diagnosed patient represents a long-term demand stream for devices, masks, tubing, filters, and humidifier chambers. As screening expands and the diagnosed population grows, PAP device demand rises directly, anchoring market growth through 2034.

Rising Obesity, Ageing Population, and Cardiometabolic Comorbidities

Excess body weight is a leading risk factor for OSA, and the global rise in obesity is enlarging the population that needs sleep apnea therapy. The World Health Organization reports that more than 1 billion people worldwide are living with obesity, while the ageing of populations in North America, Europe, Japan, and China increases the prevalence of upper-airway collapse, hypertension, heart failure, and diabetes, all of which are linked to sleep-disordered breathing. Patients with these comorbidities are more likely to be screened, diagnosed, and prescribed PAP therapy, and clinicians increasingly recognize treatment of sleep apnea as part of managing cardiometabolic disease. This demographic and epidemiological shift expands both first-time device demand and long-term resupply across the forecast period, even as new weight-management drugs reshape part of the patient pathway.

Market Restraints

Despite strong momentum, the Positive Airway Pressure Devices market faces material constraints. Poor long-term adherence remains the most significant clinical challenge, as many patients struggle with mask discomfort, pressure intolerance, dryness, claustrophobia, or noise and discontinue therapy, which limits resupply revenue and clinical outcomes. The large majority of OSA cases remain undiagnosed, reflecting limited sleep-testing capacity and low awareness in many regions. Alternative and complementary therapies are emerging, including oral appliances, hypoglossal nerve stimulation, positional therapy, and weight-loss medications, with the FDA approving tirzepatide for moderate-to-severe OSA in adults with obesity in December 2024, creating uncertainty about the long-term volume of PAP therapy starts. Reimbursement and compliance rules, competitive bidding, and payment pressure compress pricing and margins for providers and manufacturers. Product-safety concerns, highlighted by the Philips recall and its regulatory consequences, raise the compliance burden and can erode confidence in the category. Supply-chain disruption, component availability, and tariff and trade uncertainty affect cost and availability, while limited reimbursement and affordability constrain adoption in emerging economies. Together, these adherence, competitive, regulatory, and cost barriers temper growth, even as the underlying drivers of OSA prevalence, diagnosis, and home-based care remain firmly intact.

Positive Airway Pressure Devices Market Segment Analysis

The Positive Airway Pressure Devices Market is segmented by device type (continuous positive airway pressure devices, auto-titrating positive airway pressure devices, bi-level positive airway pressure devices, and others), age group (adults and pediatrics), end-user (hospitals, clinics, and homecare settings), and geography (North America, Europe, Asia-Pacific, Rest of World).

By Device Type

Dominant Subsegment: Continuous Positive Airway Pressure (CPAP) Devices.

The continuous positive airway pressure (CPAP) devices segment accounted for 52% of the Positive Airway Pressure Devices market in 2025. CPAP is the leading device type because it is the first-line, longest-established, and most widely prescribed therapy for obstructive sleep apnea, with a robust clinical evidence base, simple operation, and a lower price point than auto-titrating or bi-level systems. Fixed-pressure CPAP is also favored by payers and by providers in cost-sensitive and emerging markets, where it remains the default prescription for patients whose pressure requirements are stable and well characterized. Its large installed base generates recurring demand for masks, tubing, filters, and humidifier chambers, and replacement cycles keep volumes steady. Many devices marketed as CPAP also include auto-adjusting modes, which blur category boundaries and support upgrades. While auto-titrating (APAP) devices are among the fastest-growing categories thanks to their comfort and reduced need for in-laboratory titration, and bi-level (BiPAP) devices serve patients with higher pressure needs or complex respiratory conditions, the breadth of prescriptions, the size of the installed base, and affordability secure CPAP's leadership across the forecast period.

By Age Group

Dominant Subsegment: Adults.

The adults segment accounted for 94% of the Positive Airway Pressure Devices market in 2025. Adults dominate because OSA prevalence rises with age, body weight, and the burden of hypertension, heart disease, and diabetes, and the overwhelming majority of diagnosed patients and PAP prescriptions are in middle-aged and older adults. Established guidelines, payer coverage, and a mature diagnostic pathway make adult therapy initiation straightforward, and adult patients generate sustained resupply demand for masks and accessories over many years of therapy. Pediatrics is a much smaller segment but is expected to grow steadily as clinicians better recognize sleep-disordered breathing in children with obesity, craniofacial abnormalities, Down syndrome, and neuromuscular disease, for whom PAP is used when adenotonsillectomy is not curative or is not an option, supported by smaller pediatric-fit masks and tailored pressure settings. Nonetheless, the size of the adult OSA population and its prescription volumes secure adults' leadership across the forecast period.

Positive Airway Pressure Devices Market Region Analysis

Dominant Region: North America

North America accounted for 40% of the global Positive Airway Pressure Devices market revenue in 2025, representing the highest regional market share globally. The region's leadership reflects a high prevalence of obesity and OSA, a large diagnosed and treated patient base, well-established reimbursement through Medicare and private payers, a dense network of sleep clinics and homecare providers, and strong adoption of connected devices and telehealth, particularly in the United States. The region is home to leading manufacturers and has been the focus of the Philips Respironics recall and consent decree, which has shifted supply toward other manufacturers and increased demand for alternative platforms. High awareness, strong clinical guidelines, and rapid adoption of home sleep testing continue to expand the diagnosed population, while recurring mask and accessory resupply sustains revenue. Established reimbursement, mature care pathways, and technology adoption anchor the region's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Positive Airway Pressure Devices market. The region's elevated CAGR is driven by a very large and largely undiagnosed OSA population, rising obesity and urbanization, ageing populations, expanding sleep-medicine capacity, and growing healthcare spending across China, Japan, India, South Korea, and Australia. China and India are scaling sleep-laboratory networks and home sleep testing, Japan has an established insurance framework for CPAP therapy, and Australia is a hub for sleep medicine and device manufacturing and research. Local and regional manufacturers are launching competitively priced devices and masks, improving affordability, while multinational companies expand distribution and local partnerships. Rising awareness, improving reimbursement, and the sheer size of the untreated population position Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 40% of the global Positive Airway Pressure Devices market revenue in 2025. The United States dominates on the strength of its large OSA patient pool, Medicare and private-payer coverage, extensive homecare provider network, and rapid adoption of connected devices, while the Philips recall and consent decree have redistributed demand toward other manufacturers. Canada and Mexico contribute through expanding sleep-testing capacity and provincial and private coverage.

Europe

Europe is a large and advanced regional market, supported by universal health coverage, established sleep-medicine networks, and strong clinical-guideline adoption in Germany, France, the United Kingdom, Italy, and Spain. The region hosts major manufacturers and is governed by the EU Medical Device Regulation, which raises documentation and post-market surveillance requirements. Reimbursement approaches vary by country, with some systems rewarding documented adherence, and remote monitoring and home-based care are growing steadily.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by a large undiagnosed OSA population, rising obesity and urbanization, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Expanding sleep-laboratory capacity, home sleep testing, affordable locally manufactured devices, and improving reimbursement are accelerating regional adoption and therapy starts.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Rising obesity and diabetes, improving private healthcare infrastructure, and growing awareness of sleep apnea are gradually expanding diagnosis and therapy, while affordability and limited reimbursement remain barriers, encouraging demand for lower-cost CPAP devices and distributor partnerships.

Positive Airway Pressure Devices Market Competitive Landscape

The Positive Airway Pressure Devices market is classified as Moderately Concentrated. A group of global leaders with broad portfolios, extensive clinician and homecare relationships, and connected-care platforms, including ResMed, Koninklijke Philips N.V., and Fisher & Paykel Healthcare, anchors the top tier, while regional and specialized manufacturers such as APEX MEDICAL CORP, 3B Medical, Compumedics, Smiths Medical, ARMSTRONG MEDICAL, VYAIRE MEDICAL, and Somnera compete through price, regional distribution, specialized respiratory and sleep-diagnostics offerings, and tailored products for emerging markets, increasing competition in the fastest-growing segments.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with a few global leaders commanding a large share of the market and a long tail of regional and specialized manufacturers.
• Leading players: ResMed, Koninklijke Philips N.V., and Fisher & Paykel Healthcare anchor the top tier through broad device, mask, and software portfolios and strong clinician and homecare relationships.
• Geographic reach: Leaders operate global distribution and service networks across North America, Europe, and Asia-Pacific, while regional players such as APEX MEDICAL CORP and 3B Medical compete through local channels and competitive pricing.
• Product portfolio strength: Top players offer CPAP, APAP, and bi-level devices, heated humidifiers, a full range of masks, and consumables, supported by connectivity and patient-engagement platforms.
• Quality and regulatory standing: Compliance with FDA, EU MDR, and other regulatory requirements and a clean safety record have become decisive advantages following the Philips Respironics recall.
• Strategic partnerships: Collaborations with homecare providers, sleep-diagnostics companies, telehealth platforms, and payers extend reach and support adherence programs.
• M&A activity: Ongoing portfolio reshaping, including ICU Medical's acquisition of Smiths Medical in 2022 and the 2024 restructuring and asset sales of Vyaire Medical, alongside investment in sleep-diagnostics and software capabilities.
• Manufacturing capabilities: Scalable, quality-controlled manufacturing and resilient supply chains for blowers, sensors, and electronics are key competitive moats.
• Innovation focus: Connected and AI-enabled devices, quieter and smaller designs, improved mask comfort, remote monitoring, and integrated sleep-diagnostics and therapy platforms.

Positive Airway Pressure Devices Market Recent Developmental Activities

In 2025, ResMed reported annual revenue above USD 5 billion for fiscal 2025, supported by demand for its AirSense 11 platform, masks, and connected-care software. Strategic significance: Reinforces ResMed's position as the global market leader and signals sustained underlying demand for PAP therapy.

In December 2024, Eli Lilly and Company received FDA approval for tirzepatide as the first drug treatment for moderate-to-severe obstructive sleep apnea in adults with obesity. Strategic significance: Introduces a pharmacological option that can complement or compete with PAP therapy, prompting manufacturers to emphasize adherence, comfort, and integrated sleep-care pathways.

Positive Airway Pressure Devices Market Segmentation

Positive Airway Pressure Devices Market by Device Type

• Continuous Positive Airway Pressure Devices
• Auto-titrating Positive Airway Pressure Devices
• Bi-level Positive Airway Pressure Devices
• Others

Positive Airway Pressure Devices Market by Age Group

• Adults
• Pediatrics

Positive Airway Pressure Devices Market by End-User

• Hospitals
• Clinics
• Homecare Settings

Positive Airway Pressure Devices Market by Geography

• North America Positive Airway Pressure Devices Market
• United States Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• Canada Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• Mexico Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• Europe Positive Airway Pressure Devices Market
• Germany Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• United Kingdom Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• France Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• Italy Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• Spain Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• Rest of Europe Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• Asia-Pacific Positive Airway Pressure Devices Market
• China Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• Japan Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• India Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• Australia Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• South Korea Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• Rest of the World (RoW) Positive Airway Pressure Devices Market
• Middle East Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• Africa Positive Airway Pressure Devices Market Size in USD million (2023-2034)
• South America Positive Airway Pressure Devices Market Size in USD million (2023-2034)

Key Takeaways from the Positive Airway Pressure Devices Market Report Study

• Market size analysis for the current positive airway pressure devices market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global positive airway pressure devices market.
• Various opportunities available for competitors in the positive airway pressure devices market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current positive airway pressure devices market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for positive airway pressure devices market growth in the future?

Target audience who can benefit from this positive airway pressure devices market report study

• Positive airway pressure device manufacturers
• Research organizations and consulting companies
• Positive airway pressure devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors, homecare providers, and traders dealing in positive airway pressure devices
• Various end-users, including hospitals, clinics, and homecare providers, who want to know more about the positive airway pressure devices market and the latest technological developments in the market.

Frequently Asked Questions:

Q1. What is the growth rate of the Positive Airway Pressure Devices market?

The Positive Airway Pressure Devices market is projected to expand at a CAGR of 7.0% during the forecast period from 2026 to 2034.

Q2. What is the market size of the Positive Airway Pressure Devices market?

The Positive Airway Pressure Devices market is estimated at USD 4.85 billion in 2025 and is projected to reach USD 8.92 billion by 2034.

Q3. Which region dominates the Positive Airway Pressure Devices market?

North America dominated the Positive Airway Pressure Devices market with a 40% share of global revenue in 2025, supported by a high prevalence of obesity and OSA, strong reimbursement, a dense network of sleep clinics and homecare providers, and rapid adoption of connected devices. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Positive Airway Pressure Devices market?

The principal drivers are the rising prevalence of obstructive sleep apnea, with an estimated 936 million adults aged 30 to 69 affected worldwide; rising obesity, population ageing, and cardiometabolic comorbidities; expanding diagnosis through home sleep testing; technological innovation in connected and auto-adjusting devices; the shift toward home care supported by reimbursement; and replacement demand following the Philips Respironics recall.

Q5. Who are the major players in the Positive Airway Pressure Devices market?

The major players include ResMed, Koninklijke Philips N.V., Fisher & Paykel Healthcare Limited, APEX MEDICAL CORP, ARMSTRONG MEDICAL (an EAKIN Company), Smiths Medical, Compumedics Limited, VYAIRE MEDICAL, INC., Somnera Inc., and 3B Medical Inc., among other active providers profiled in the Competitive Landscape section. ResMed, Philips, and Fisher & Paykel Healthcare lead through broad portfolios and global reach.